Press releases

Company made the announcement at the annual Paris Course on Revascularization (EuroPCR).

Boston Scientific's second-generation stent system now approved for treatment of acute mycocardial infarction, total occlusions and in-stent restenosis

Cardiac Rhythm Management (CRM) Group is formerly Guidant's CRM business; Boston Scientific acquired Guidant on April 21

Court also upheld its earlier decision dismissing the TAXUS® Liberte™ product from the case, without prejudice

Pending approval from the Board of Directors, Dr. Baim will also join Boston Scientific's Executive Committee

Boston Scientific is the exclusive U.S. distributor of this product for a new treatment option for female stress urinary incontinence

Results to include nine-month data on TAXUS® Liberte™

Lawsuit alleges that the Conor CoStar™ Paclitaxel-Eluting Coronary Stent System infringes a balloon catheter patent owned by Boston Scientific

Court finds Sahajanand's Infinnium paclitaxel-eluting stent infringed two claims of an Angiotech patent

Endoscopic vessel harvesting speeds recovery and reduces pain and scarring; new products offer clinicians more choices to improve patient outcomes

A live webcast and replay of the May 4 conference session will be available

A live webcast and replay of the May 2 conference session will be available

Includes recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs)

Both were members of the board of directors of Guidant Corporation, which was acquired by the Company last week

Company elected to adjust the interest rates due to the closing of the Company's acquisition of Guidant Corporation

Creates a global leader in cardiovascular devices and one of the largest medical technology companies in the world

Transaction scheduled to close tomorrow

"We are very pleased that we achieved record company sales for the quarter," said Jim Tobin, President and Chief Executive Officer

New study seeks to define potential of Precision™ system to treat large population of U.S. migraine sufferers who don't respond adequately to current therapies

Company must also receive antitrust approval from the U.S. Federal Trade Commission (FTC) before it can close the Guidant transaction

A live webcast and replay of the April 18 conference call will be available

Agreement subject to approval by FTC Commissioners

Company's newest addition to its broad portfolio of vascular access products

At separate special meetings today, shareholders of each company have voted overwhelmingly to approve

Features a number of elements designed to enhance steering, handling and tracking during peripheral and coronary procedures